浅析基因驱动可专利性争议
A Brief Analysis of the Patentability Controversy of Gene Drive
DOI: 10.12677/ds.2025.111008, PDF,   
作者: 王艺珺：华东政法大学国际法学院，上海
关键词: 基因驱动；基因可专利性；生物技术与法律；Gene Drive； Gene Patentability； Biotechnology and Law
摘要: 近年来，满足人类需求的生物技术发明不断涌现。基因驱动作为一项新兴技术，给生物技术带来了新的活力。然而，它也面临着许多问题，本文以基因驱动的可专利性为重点，探索不同的基因专利保护途径，从而平衡基因驱动的优点和缺点。文章简要介绍了基因驱动的定义，并阐述了基因驱动在传染病防治和农业中的应用。本文也探究了基因专利保护的不同途径，特别是美国和欧洲所采取的具有深远影响的方法，通过分析基因专利的潜在风险，如食品供应短缺和公共卫生风险，试图全面分析基因专利带来的影响。
Abstract: In recent years, biotechnological inventions that meet human needs are constantly sprouting. Gene drive, as an emerging technology, has brought new vitality to biotechnology. However, it also faces many problems. This paper focuses on the patentability of gene drive and tries to figure out different approaches to gene patent protection, thus striking a balance between the merits and demerits of gene drive. The paper briefly introduces the definition of gene drive and helps to figure out how gene drive applies in the prevention and control of infectious diseases and agriculture. Also, this paper explores the different approaches to gene patent protection, in particular the far-reaching approaches taken in the United States and Europe, and attempts to comprehensively analyze the full implications of gene patents by analyzing the potential risks of gene patents, such as food supply shortages and public health risks.
文章引用：王艺珺. 浅析基因驱动可专利性争议[J]. 争议解决, 2025, 11(1): 47-53. https://doi.org/10.12677/ds.2025.111008

参考文献

[1] Clark, D.P. and Pazdernik, N.J. (2015) Biotechnology: Academic Cell Update. Elsevier, 21-23.
[2] Curtis, C.F. (1968) Possible Use of Translocations to Fix Desirable Genes in Insect Pest Populations. Nature, 218, 368-369. [Google Scholar] [CrossRef] [PubMed]
[3] Nag, P.K. and Gite, L.P. (2020) Human-Centered Agriculture. Springer. [Google Scholar] [CrossRef] 
[4] Anderson, E.L. (2012) Finding a Fit: Gene Patents and Innovation Policy. UC Law Science and Technology Journal, 4, Article 357.
[5] Barraclough, E. (2013) What Myriad Means for Biotech. WIPO Magazine, 4, 21-23.
[6] Mashburn, D.D. (2011) Patenting Eden: Limiting Human Gene Ownership. UMKC Law Review, 80, 173.
[7] Robinson, J.M. (2016) A Myriad of Controversy over the Question of Human Gene Patent Eligibility: A Comparison of the Differing Approaches in the United States and Australia. Houston Journal of International Law, 38, 913.
[8] 刘鑫. 基因技术专利化的问题、争议与应对[J]. 电子知识产权, 2021(8): 3-17.
[9] 辛玲玲. 我国基因专利保护范围的问题研究[D]: [硕士学位论文]. 广州: 华南理工学, 2020.
[10] 肖鹏. 我国人类基因专利现状分析与对策建议[J]. 湖北警官学院学报, 2024, 37(1): 5-14.
[11] Kennedy, D. (2009) A Critique of Adjudication. Harvard University Press.
[12] 赵雷. 美国2011年专利法第一案Myriad案评——人类基因可专利性的再思考[J]. 知识产权, 2012(6): 89-95.
[13] Gold, E.R. and Gallochat, A. (2001) The European Biotech Directive: Past as Prologue. European Law Journal, 7, 331-366. [Google Scholar] [CrossRef] 
[14] Gold, E.R. and Carbone, J. (2010) Myriad Genetics: In the Eye of the Policy Storm. Genetics in Medicine, 12, S39-S70. [Google Scholar] [CrossRef] [PubMed]
[15] Cole, P. (2014) Patentability of Genes: A European Union Perspective. Cold Spring Harbor Perspectives in Medicine, 5, a020891. [Google Scholar] [CrossRef] [PubMed]
[16] Correa, C.M. (2005) The TRIPS Agreement and Developing Countries. In: International Trade Law Center, Appleton, A.E. and Plummer, M.G., Eds., The World Trade Organization: Legal, Economic and Political Analysis, Springer, 2021-2046.
[17] 孟雨. 国际贸易框架下食品安全相关法律问题研究[J]. 北京化工大学学报(社会科学版), 2010(2): 7-12, 6.
[18] 仇华飞, 涂明辉. 全球公共卫生治理的规范碰撞与变迁——以世界卫生组织与TRIPS协议为例[J]. 国际关系研究, 2024(1): 19-40, 155-156.
[19] 张语嫣. 《TRIPS》协议的药品专利“公共非商业用途”强制许可: 以发展中国家基本药物可及性为视角[J]. 北大国际法与比较法评论, 2024, 18(1): 31-72.
[20] 皇甫洁琼, 钟彦. 专利药品可及性的现实困境和制度优化——兼评药品专利池组织的运营[J]. 中国新药杂志, 2024, 33(9): 864-867.
[21] 陈明月, 杨田甜. 医药知识产权与健康权之平衡——以强制许可制度为视角[J]. 卫生法学, 2024, 32(4): 65-72.

为你推荐